Soleno Therapeutics, Inc.

NasdaqCM:SLNO Stock Report

Market Cap: US$2.0b

Soleno Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

NasdaqCM:SLNO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
03 Jan 25SellUS$138,709Patricia HiranoIndividual3,030US$46.18
03 Jan 25SellUS$222,484Kristen YenIndividual4,860US$46.18
03 Jan 25SellUS$965,516Anish BhatnagarIndividual21,091US$46.18
03 Jan 25SellUS$360,460James MacKanessIndividual7,874US$46.18
19 Nov 24SellUS$41,802,720Perceptive Advisors LLCCompany813,208US$57.21
23 Oct 24SellUS$32,854,156Perceptive Advisors LLCCompany647,471US$54.53
17 Oct 24SellUS$27,000,504Abingworth LLPCompany499,047US$54.56
08 Oct 24SellUS$45,503,055Abingworth LLPCompany849,897US$53.67
01 Oct 24SellUS$1,069,306Anish BhatnagarIndividual21,633US$50.25
01 Oct 24SellUS$153,627Patricia HiranoIndividual3,108US$50.25
01 Oct 24SellUS$399,241James MacKanessIndividual8,077US$50.25
01 Oct 24SellUS$153,627Kristen YenIndividual3,108US$50.25
29 Aug 24SellUS$49,210,750Vivo Capital, LLCCompany1,025,000US$48.73
29 Aug 24SellUS$5,454,707Anish BhatnagarIndividual115,004US$48.03
29 Aug 24SellUS$507,745Patricia HiranoIndividual10,705US$48.03
29 Aug 24SellUS$641,783James MacKanessIndividual13,531US$48.03
29 Aug 24SellUS$507,745Kristen YenIndividual10,705US$48.03
06 Aug 24SellUS$5,806,696Anish BhatnagarIndividual127,344US$46.14
06 Aug 24SellUS$501,994Patricia HiranoIndividual11,009US$46.14
06 Aug 24SellUS$683,202James MacKanessIndividual14,983US$46.14
06 Aug 24SellUS$500,398Kristen YenIndividual10,974US$46.14
01 Jul 24SellUS$799,844Anish BhatnagarIndividual19,256US$41.63
01 Jul 24SellUS$298,654James MacKanessIndividual7,190US$41.63
01 Jul 24SellUS$90,136Patricia HiranoIndividual2,170US$41.63
01 Jul 24SellUS$90,136Kristen YenIndividual2,170US$41.63
30 Apr 24SellUS$51,701,551Vivo Capital, LLCCompany1,101,242US$47.80
01 Apr 24SellUS$91,694Kristen YenIndividual2,218US$41.67
01 Apr 24SellUS$91,694Patricia HiranoIndividual2,218US$41.67
01 Apr 24SellUS$784,645Anish BhatnagarIndividual18,980US$41.67
01 Apr 24SellUS$213,937James MacKanessIndividual5,175US$41.67

Insider Trading Volume

Insider Buying: SLNO insiders have only sold shares in the past 3 months.


Ownership Breakdown

What is the ownership structure of SLNO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,096,5792.07%
VC/PE Firms6,291,85111.8%
Hedge Funds9,229,94217.4%
Institutions36,478,36368.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 41.4%.


Top Shareholders

Top 25 shareholders own 98.82% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.6%
Vivo Capital, LLC
6,291,851US$290.2m0%29.55%
12%
Janus Henderson Group plc
5,188,265US$239.3m27.1%0.1%
9.11%
Nantahala Capital Management, LLC
3,928,966US$181.2m20.1%12.37%
6.44%
Adage Capital Management, L.P.
2,775,976US$128.1m-16.4%0.22%
5.86%
Avoro Capital Advisors LLC
2,525,000US$116.5m15.8%1.59%
4.66%
BlackRock, Inc.
2,009,790US$92.7m-0.1%no data
4.37%
The Vanguard Group, Inc.
1,884,533US$86.9m19.2%no data
3.78%
T. Rowe Price Group, Inc.
1,630,718US$75.2m24.5%0.01%
3.54%
Commodore Capital LP
1,525,000US$70.3m21%5.57%
3.48%
Perceptive Advisors LLC
1,501,040US$69.2m-53.2%1.96%
3.19%
Abingworth LLP
1,375,646US$63.5m-66.2%59.94%
3.12%
State Street Global Advisors, Inc.
1,347,019US$62.1m17.9%no data
2.46%
Vestal Point Capital, LP
1,060,000US$48.9m47.2%3.06%
2.26%
Citadel Advisors LLC
972,410US$44.9m4,370%0.04%
2.22%
Holocene Advisors, LP
955,467US$44.1m60.8%0.14%
2.2%
Emerald Advisers, LLC
949,493US$43.8m73.8%1.05%
2.04%
Westfield Capital Management Company, L.P.
881,460US$40.7m77.8%0.17%
1.98%
Pictet Asset Management Limited
851,838US$39.3m48%0.03%
1.89%
FMR LLC
813,016US$37.5m22.2%no data
1.81%
Wellington Management Group LLP
782,265US$36.1m14.5%0.01%
1.76%
Sofinnova Investment, Inc.
757,248US$34.9m29.2%2.64%
1.74%
Anish Bhatnagar
752,362US$34.7m4.56%no data
1.62%
Frazier Life Sciences Management, LP
699,159US$32.3m-20.2%1.39%
1.39%
Geode Capital Management, LLC
599,119US$27.6m10.9%no data
1.28%
TCG Crossover Management, LLC
550,000US$25.4m0%3.09%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/22 22:44
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Soleno Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Kristen KluskaCantor Fitzgerald & Co.
François BriseboisCraig-Hallum Capital Group LLC